Jim Tananbaum is the Founder & CEO of Foresite Capital who created the company back in 2011 as a healthcare-dedicated private equity firm specializing in providing emerging healthcare leaders with the tools they need to help increase profitability by supplying capital, networks, and information to them to help them do their jobs better. Prior to founding Foresite Capital, Tananbaum worked with two additional huge biopharmaceutical companies and also two other large companies also invested in healthcare. Tananbaum also cofounded and was the CEO of another successful company Theravance Inc. Tananbaum’s investment experiences included being partners in investing in both Prospect Venture Partners II & III as well as a partnership with Sierra Ventures. Numerous other investments include Amira Pharmaceuticals, Amerigroup, Healtheon, and Jazz Pharmaceuticals to name a few others. Tananbaum believes that innovation is at the heart of providing customers with better health care experiences and the chance to live healthier, happier, and longer lives in the future. There are so many unmet needs in healthcare that entrepreneurs can help meet that it can be a very lucrative business. That’s what inspired Tananbaum to get into healthcare of all industries.Visit Crunchbase to know more.
Jim Tananbaum still calls himself an academic at heart, no matter what field of work he gets into. Tananbaum is a graduate of the Harvard Business School who resides in the San Francisco Bay Area. Tananbaum currently works with insurance companies that provide healthcare services in many different areas including biotechnology, genomics, diagnostics, healthcare services, and medical devices to name a few areas of focus. Tananbaum’s Foresite Capital also runs locations out of New York City and Philadelphia and is the project Tananbaum created after running other $1 billion + companies in the past. Check out LinkedIn Forsite Capital.
Jim Tananbaum is also focusing his effort on the obesity epidemic that has taken over this planet. Over 350 million people globally and that population is growing. Tananbaum’s company also takes on glaucoma which affects over 40 million people and is the leading cause of blindness in the world. They also lead in pharmaceuticals, gene sequencing, and synthetic biology as well as many other cutting-edge field. Tananbaum seeks to expand his company further in the future to continue to help many people as possible through advancing technologies his company offers and to help make people’s lives better and longer. More details can be found on LinkedIn.
Visit his Facebook page